TY - JOUR
T1 - Pediatric Multiple Sclerosis Severity Score in a large US cohort
AU - Santoro, Jonathan D.
AU - Waltz, Michael
AU - Aaen, Greg
AU - Belman, Anita
AU - Benson, Leslie
AU - Gorman, Mark
AU - Goyal, Manu S.
AU - Graves, Jennifer S.
AU - Harris, Yolanda
AU - Krupp, Lauren
AU - Lotze, Timothy
AU - Mar, Soe
AU - Moodley, Manikum
AU - Ness, Jayne
AU - Rensel, Mary
AU - Rodriguez, Moses
AU - Schreiner, Teri
AU - Tillema, Jan Mendelt
AU - Waubant, Emmanuelle
AU - Weinstock-Guttman, Bianca
AU - Hurtubise, Brigitte F.
AU - Roalstad, Shelly
AU - Rose, John
AU - Casper, T. Charles
AU - Chitnis, Tanuja
N1 - Funding Information:
J.D. Santoro has received educational grant funding from the American Academy of Neurology and Biogen. M. Waltz, G. Aean, A. Belman, and L. Benson report no disclosures relevant to the manuscript. M. Gorman receives research funding from Pfizer for research unrelated to the current manuscript and from the National Multiple Sclerosis Society and has received research funding as a site PI for Biogen and Novartis trials. M.S. Goyal, J.S. Graves, and Y. Harris report no disclosures relevant to the manuscript. L. Krupp has received compensation for her role in DSMBs for Biogen and Sanofi and has received licensing fees from the Fatigue Severity Scale from pharmaceutical and biotechnology companies. T. Lotze, S. Mar, M. Moodley, and J. Ness report no disclosures relevant to the manuscript. M. Resnsel serves on the advisory board of Serono and Biogen; is a consultant for Biogen, Teva, Genzyme, and Novartis; has received commercial research support from Medimmune and Genentech; has received foundation/society research support from the National Multiple Sclerosis Society; has received educational grants from Genzyme; and is part of the speakers bureau at Novartis, Genzyme, and Biogen. M. Rodriguez, T. Schreine, and J. Tilema report no disclosures relevant to the manuscript. E. Waubant has received personal honoraria from American Academy of Neurology, American Neurologic Association, Jazz Pharmaceuticals, Emerald, and DBV; is site PI for a Biogen and Roche trial; volunteers on an advisory board for a Novartis trial; is a nonremunerated advisor for clinical trial design for Roche, Serono, and Celgene; has funding from the NIH, NMSS, PCORI, and the Race to Erase MS; and is co–Chief editor for MSARD. B. Weinstock-Guttman has received consulting fees from Biogen, EMD Serono, Genentech, Novartis, Mallinckrodt, and Celgene; and has received research support from Biogen, Novartis, Genentech, and Novartis. B.F. Hurtubise, S. Roalstad, J. Rose, and T.C. Casper report no disclosures relevant to the manuscript. T. Chitnis has received research funding from Serono, Novartis, and Verily and has participated as a consultant or advisor for Biogen, Novartis, and Sanofi-Genzyme. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
© American Academy of Neurology.
PY - 2020/9/29
Y1 - 2020/9/29
N2 - Objective: To characterize disease severity and distribution of disability in pediatric-onset multiple sclerosis (POMS) and to develop an optimized modeling scale for measuring disability, we performed a multicenter retrospective analysis of disability scores in 873 persons with POMS over time and compared this to previously published data in adults with multiple sclerosis (MS). Methods: This was a retrospective analysis of prospectively collected data collected from 12 centers of the US Network of Pediatric MS Centers. Patients were stratified by the number of years from first symptoms of MS to Expanded Disability Status Scale (EDSS) assessment and an MS severity score (Pediatric Multiple Sclerosis Severity Score [Ped-MSSS]) was calculated per criteria developed by Roxburgh et al. in 2005. Results: In total, 873 patients were evaluated. In our cohort, 52%, 19.4%, and 1.5% of all patients at any time point reached an EDSS of 2.0, 3.0, and 6.0. Comparison of our Ped-MSSS scores and previously published adult Multiple Sclerosis Severity Scores (MSSS) showed slower progression of Ped-MSSS with increasing gaps between higher EDSS score and years after diagnosis. Decile scores in our POMS cohort for EDSS of 2.0, 3.0, and 6.0 were 8.00/9.46/9.94, 7.86/9.39/9.91, and 7.32/9.01/9.86 at 2, 5, and 10 years, respectively. Notable predictors of disease progression in both EDSS and Ped-MSSS models were ever having a motor relapse and EDSS at year 1. Symbol Digit Modalities Test (SDMT) scores were inversely correlated with duration of disease activity and cerebral functional score. Conclusions: Persons with POMS exhibit lower EDSS scores compared to persons with adult-onset MS. Use of a Ped-MSSS model may provide an alternative to EDSS scoring in clinical assessment of disease severity and disability accrual.
AB - Objective: To characterize disease severity and distribution of disability in pediatric-onset multiple sclerosis (POMS) and to develop an optimized modeling scale for measuring disability, we performed a multicenter retrospective analysis of disability scores in 873 persons with POMS over time and compared this to previously published data in adults with multiple sclerosis (MS). Methods: This was a retrospective analysis of prospectively collected data collected from 12 centers of the US Network of Pediatric MS Centers. Patients were stratified by the number of years from first symptoms of MS to Expanded Disability Status Scale (EDSS) assessment and an MS severity score (Pediatric Multiple Sclerosis Severity Score [Ped-MSSS]) was calculated per criteria developed by Roxburgh et al. in 2005. Results: In total, 873 patients were evaluated. In our cohort, 52%, 19.4%, and 1.5% of all patients at any time point reached an EDSS of 2.0, 3.0, and 6.0. Comparison of our Ped-MSSS scores and previously published adult Multiple Sclerosis Severity Scores (MSSS) showed slower progression of Ped-MSSS with increasing gaps between higher EDSS score and years after diagnosis. Decile scores in our POMS cohort for EDSS of 2.0, 3.0, and 6.0 were 8.00/9.46/9.94, 7.86/9.39/9.91, and 7.32/9.01/9.86 at 2, 5, and 10 years, respectively. Notable predictors of disease progression in both EDSS and Ped-MSSS models were ever having a motor relapse and EDSS at year 1. Symbol Digit Modalities Test (SDMT) scores were inversely correlated with duration of disease activity and cerebral functional score. Conclusions: Persons with POMS exhibit lower EDSS scores compared to persons with adult-onset MS. Use of a Ped-MSSS model may provide an alternative to EDSS scoring in clinical assessment of disease severity and disability accrual.
UR - http://www.scopus.com/inward/record.url?scp=85091956813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091956813&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000010414
DO - 10.1212/WNL.0000000000010414
M3 - Article
C2 - 32690790
AN - SCOPUS:85091956813
SN - 0028-3878
VL - 95
SP - E1844-E1853
JO - Neurology
JF - Neurology
IS - 13
ER -